Author:
Albertsson Per,Bäck Tom,Bergmark Karin,Hallqvist Andreas,Johansson Mia,Aneheim Emma,Lindegren Sture,Timperanza Chiara,Smerud Knut,Palm Stig
Abstract
Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献